Blood donors on teratogenic drugs and donor deferral periods in a clinical situation.
Deferral of blood donors taking teratogenic drugs is critical. From March 2008 to January 2009, we analysed stored blood specimens from donors who had taken teratogenic drugs and whose blood was transfused to women of childbearing age to determine the plasma concentration at the time of donation using high-performance liquid chromatography. In total, 167 specimens were examined. The numbers of specimens exceeding the quantification limit were 7, 39, 4, 2 and 1 for finasteride, isotretinoin, acitretin, etretinate and dutasteride, respectively. Finasteride was beyond the recommended drug deferral period in one specimen. These results may help create practical deferral policies.
Division of Human Blood Safety Surveillance, Korea Centers for Disease Control and Prevention, Osong Health Technology Administration Complex, South Korea.
S Y
SY
Shin
Y H
YH
Shin
S W
SW
Lee
J Y
JY
Shin
C H
CH
Kim
D017255:Acitretin / Q000097:blood; D000328:Adult; D001782:Blood Donors; D005050:Etretinate / Q000097:blood; D005260:Female; D018120:Finasteride / Q000097:blood; D006801:Humans; D013723:Teratogens / Q000032:analysis*; D065227:Transfusion Reaction; D055815:Young Adult
D013723:Teratogens; D018120:Finasteride; D005050:Etretinate; D017255:Acitretin